After Evercore ISI and Robert W. Baird gave Mirum Pharmaceuticals (NASDAQ: MIRM) a Buy rating last month, the company received another Buy, this time from SVB Securities. Analyst Mani Foroohar maintained a Buy rating on Mirum Pharmaceuticals today and set a price target of $52.00. The company's shares closed last Monday at $25.23. According to TipRanks.com, Foroohar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -23.2% and a 33.5% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Arrowhead Pharmaceuticals, and 4D Molecular Therapeutics.
https://www.tipranks.com/news/blurbs/mirum-pharmaceuticals-mirm-received-its-third-buy-in-a-row?utm_source=advfn.com&utm_medium=referral
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Mirum Pharmaceuticals Charts.
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Mirum Pharmaceuticals Charts.